- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02213081
Ulipristal for Endometriosis-related Pelvic Pain
September 27, 2016 updated by: Serdar Bulun, Northwestern University
Phase IV Pilot Study of Ulipristal Acetate for Treatment of Endometriosis-related Pelvic Pain
The aim of this research is to assess the benefit of a medication (ulipristal) for alleviation of symptoms in women with chronic, endometriosis-related pelvic pain.
Study Overview
Detailed Description
This study will assess the use of a medication to improve symptoms of chronic, endometriosis-related pelvic pain among women who did no achieve relief with prior surgical and medical treatments.
Study Type
Interventional
Enrollment (Anticipated)
25
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern University, Prentice Women's Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Diagnosis of endometriosis with surgical confirmation via laparoscopy performed within 3 years prior to study enrollment
- English-speaking reproductive-age women (18-50yo) with regular, cyclical menses
- Treatment-refractory endometriosis, as defined by persistent or recurrent pelvic pain following one or more treatments involving surgery and/or hormonal treatment
- Dysmenorrhea and chronic pelvic pain for a least one week out of the month during past 5 months or longer
- Endometrial biopsy before and after intervention
- Adequate organ and marrow function as defined below:
- leukocytes ≥ 3,000/microliter
- absolute neutrophil count ≥ 1,500/microliter
- platelets ≥ 100,000/microliter
- total bilirubin within normal institutional limits
- Liver function tests ≤ 2.5 X institutional upper limit of normal
- creatinine within normal institutional limits
- Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
- A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:
- Has not undergone a hysterectomy or bilateral oophorectomy; or
- Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).
- Ability to understand and the willingness to sign a written informed consent.
Exclusion Criteria:
- Undiagnosed vaginal bleeding
- Abnormal results from endometrial biopsy
- Presence of ovarian cysts ≥ 3 cm
- Pregnancy
- Refusal to adhere the birth control strategy of the study (use of a combination of a condom and a vaginal sponge during each intercourse while on ulipristal, plus one month before the onset and one month after the completion of ulipristal therapy)
- Women taking digoxin, dabigatran or etexilate due to interference of ulipristal acetate with the concentration of these substances bound by plasma proteins.
- Women taking moderate to potent inducers of hepatic metabolism (e.g. erythromycin, ketoconazole, ritonavir, nefazodone).
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to Ulipristal.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active pulmonary, cardiac, renal, hepatic or thromboembolic disease, infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ulipristal
25 patients with chronic, endometriosis-related pelvic pain refractory to medical and/or surgical therapies will receive 15mg ulipristal every other day (three times a week- Monday, Thursday, Saturday) for three months.
|
Patients will take 15mg every other day, or every 4 days per week.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pelvic Pain
Time Frame: 5 months
|
Patients will document self-reported weekly average pelvic pain scores for one month prior to starting treatment, while receiving treatment for 3 months and for one full month subsequent to treatment.
|
5 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Vaginal bleeding
Time Frame: 5 months
|
Patients will record the # of tampons or pads they use each week while enrolled in the study (1 month pre-medication, 3 months during medication, 1 month after medication).
|
5 months
|
Pain with sexual intercourse
Time Frame: 5 months
|
If sexually active, patients will document self-reported weekly average pelvic pain scores with sexual intercourse for one month prior to starting treatment, while receiving treatment for 3 months and for one full month subsequent to treatment.
|
5 months
|
Serum hormone levels
Time Frame: 5 months
|
Serum levels of hormones that regulate the menstrual cycle will be assessed one month prior to starting treatment, while receiving treatment for 3 months and at one month subsequent to treatment.
|
5 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pain with bowel movements
Time Frame: 5 months
|
Patients will document self-reported weekly average pelvic pain scores with defecation for one month prior to starting treatment, while receiving treatment for 3 months and for one full month subsequent to treatment.
|
5 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Serdar Bulun, Northwestern University, Northwestern Memorial Hopsital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2015
Primary Completion (Anticipated)
June 1, 2017
Study Completion (Anticipated)
June 1, 2018
Study Registration Dates
First Submitted
August 7, 2014
First Submitted That Met QC Criteria
August 8, 2014
First Posted (Estimate)
August 11, 2014
Study Record Updates
Last Update Posted (Estimate)
September 29, 2016
Last Update Submitted That Met QC Criteria
September 27, 2016
Last Verified
September 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STU00091840
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Endometriosis
-
Fabio BarraCompletedEndometriosis | Endometriosis, Rectum | Endometriosis of Vagina | Endometriosis Rectovaginal Septum | Endometriosis Pelvic | Endometriosis of ColonItaly
-
Ospedale Policlinico San MartinoCompletedEndometriosis | Bowel Endometriosis | Endometriosis, Rectum | Endometriosis ColonItaly
-
BioGene Pharmaceutical Ltd.WithdrawnSafety, Tolerability and Efficacy of Vaginal Suppositories for Treatment of the Endometriosis (ELTA)Endometriosis | Endometriosis Ovary | Endometriosis, Rectum | Endometriosis ExternaSwitzerland
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...CompletedEndometriosis | Endometriosis-related Pain | Endometriosis Thoracic | Endometriosis of Lung | Endometriosis of PleuraItaly
-
Ospedale Policlinico San MartinoCompletedEndometriosis, Rectum | Endometriosis, SigmoidItaly
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaUnknownBowel Endometriosis | Endometriosis, RectumItaly
-
Ospedale Policlinico San MartinoActive, not recruitingEndometriosis, Rectum | Endometriosis of ColonItaly
-
Catholic University of the Sacred HeartCompletedPelvic Endometriosis | Endometriosis Outside PelvisItaly
-
Semmelweis UniversityUniversity of PecsNot yet recruitingEndometriosis | Endometriosis Ovary | Endometriosis Rectovaginal Septum
-
Catholic University of the Sacred HeartCompletedPelvic Endometriosis | Endometriosis Outside PelvisItaly
Clinical Trials on Ulipristal
-
PregLem SACompletedUterine FibroidsUnited Kingdom, Belgium, Czechia, France, Germany, Hungary, Italy, Latvia, Lithuania, Romania, Ukraine
-
Eunice Kennedy Shriver National Institute of Child...HRA PharmaCompletedLeiomyomaUnited States
-
PregLem SACompletedUterine MyomasCzech Republic, Hungary, India, Romania, Russian Federation, Ukraine
-
Stanford UniversityCompleted
-
Population CouncilUnknown
-
Northwestern UniversitySociety of Family PlanningRecruitingContraception | Contraceptive Usage | Reproductive IssuesUnited States
-
Instituto Valenciano de Infertilidad, IVI VALENCIATerminated
-
Manchester University NHS Foundation TrustUniversity of ManchesterCompleted
-
BayerTerminated
-
Fundació Institut de Recerca de l'Hospital de la...UnknownTreatment Side Effects | Leiomyoma, Uterine | Liver InjurySpain